120 related articles for article (PubMed ID: 38526805)
21. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
22. Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Goldman JW; Piha-Paul SA; Curti B; Pedersen KS; Bauer TM; Groenland SL; Carvajal RD; Chhaya V; Kirby G; McGlinchey K; Hammond SA; Streicher K; Townsley DM; Chae YK; Voortman J; Marabelle A; Powderly J
Clin Cancer Res; 2022 Sep; 28(17):3709-3719. PubMed ID: 35699623
[TBL] [Abstract][Full Text] [Related]
23. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Kim TW; Burris HA; de Miguel Luken MJ; Pishvaian MJ; Bang YJ; Gordon M; Awada A; Camidge DR; Hodi FS; McArthur GA; Miller WH; Cervantes A; Chow LQ; Lesokhin AM; Rutten A; Sznol M; Rishipathak D; Chen SC; Stefanich E; Pourmohamad T; Anderson M; Kim J; Huseni M; Rhee I; Siu LL
Clin Cancer Res; 2022 Aug; 28(16):3452-3463. PubMed ID: 35699599
[TBL] [Abstract][Full Text] [Related]
24. A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers.
Diab A; Hamid O; Thompson JA; Ros W; Eskens FALM; Doi T; Hu-Lieskovan S; Klempner SJ; Ganguly B; Fleener C; Wang X; Joh T; Liao K; Salek-Ardakani S; Taylor CT; Chou J; El-Khoueiry AB
Clin Cancer Res; 2022 Jan; 28(1):71-83. PubMed ID: 34615725
[TBL] [Abstract][Full Text] [Related]
25. Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.
Mascarelli DE; Rosa RSM; Toscaro JM; Semionatto IF; Ruas LP; Fogagnolo CT; Lima GC; Bajgelman MC
Front Cell Dev Biol; 2021; 9():692982. PubMed ID: 34277638
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Duhen R; Ballesteros-Merino C; Frye AK; Tran E; Rajamanickam V; Chang SC; Koguchi Y; Bifulco CB; Bernard B; Leidner RS; Curti BD; Fox BA; Urba WJ; Bell RB; Weinberg AD
Nat Commun; 2021 Feb; 12(1):1047. PubMed ID: 33594075
[TBL] [Abstract][Full Text] [Related]
27. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Gutierrez M; Moreno V; Heinhuis KM; Olszanski AJ; Spreafico A; Ong M; Chu Q; Carvajal RD; Trigo J; Ochoa de Olza M; Provencio M; De Vos FY; De Braud F; Leong S; Lathers D; Wang R; Ravindran P; Feng Y; Aanur P; Melero I
Clin Cancer Res; 2021 Jan; 27(2):460-472. PubMed ID: 33148673
[TBL] [Abstract][Full Text] [Related]
28. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Jardim DL; Goodman A; de Melo Gagliato D; Kurzrock R
Cancer Cell; 2021 Feb; 39(2):154-173. PubMed ID: 33125859
[TBL] [Abstract][Full Text] [Related]
29. Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors.
Glisson BS; Leidner RS; Ferris RL; Powderly J; Rizvi NA; Keam B; Schneider R; Goel S; Ohr JP; Burton J; Zheng Y; Eck S; Gribbin M; Streicher K; Townsley DM; Patel SP
Clin Cancer Res; 2020 Oct; 26(20):5358-5367. PubMed ID: 32816951
[TBL] [Abstract][Full Text] [Related]
30. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.
Subbiah V; Solit DB; Chan TA; Kurzrock R
Ann Oncol; 2020 Sep; 31(9):1115-1118. PubMed ID: 32771306
[No Abstract] [Full Text] [Related]
31. Th1 responses in vivo require cell-specific provision of OX40L dictated by environmental cues.
Gajdasik DW; Gaspal F; Halford EE; Fiancette R; Dutton EE; Willis C; Rückert T; Romagnani C; Gerard A; Bevington SL; MacDonald AS; Botto M; Vyse T; Withers DR
Nat Commun; 2020 Jul; 11(1):3421. PubMed ID: 32647184
[TBL] [Abstract][Full Text] [Related]
32. Elevated
Gu S; Zi J; Han Q; Song C; Ge Z
Cancer Cell Int; 2020; 20():146. PubMed ID: 32390761
[TBL] [Abstract][Full Text] [Related]
33. Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy.
Kim JH; Kim BS; Lee SK
Immune Netw; 2020 Feb; 20(1):e4. PubMed ID: 32158592
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity.
Fu Y; Lin Q; Zhang Z; Zhang L
Acta Pharm Sin B; 2020 Mar; 10(3):414-433. PubMed ID: 32140389
[TBL] [Abstract][Full Text] [Related]
35. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
[TBL] [Abstract][Full Text] [Related]
37. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.
Deng J; Zhao S; Zhang X; Jia K; Wang H; Zhou C; He Y
Onco Targets Ther; 2019; 12():7347-7353. PubMed ID: 31564917
[TBL] [Abstract][Full Text] [Related]
38. High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer.
Sawada R; Arai Y; Sagawa Y; Nagata Y; Nishimura T; Noguchi M; Amano K; Arihiro S; Saruta M; Homma S
Oncol Rep; 2019 Nov; 42(5):2057-2064. PubMed ID: 31545443
[TBL] [Abstract][Full Text] [Related]
39. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.
Polesso F; Sarker M; Weinberg AD; Murray SE; Moran AE
J Immunol; 2019 Oct; 203(7):2011-2019. PubMed ID: 31434709
[TBL] [Abstract][Full Text] [Related]
40. Central Roles of OX40L-OX40 Interaction in the Induction and Progression of Human T Cell-Driven Acute Graft-versus-Host Disease.
Tripathi T; Yin W; Xue Y; Zurawski S; Fujita H; Hanabuchi S; Liu YJ; Oh S; Joo H
Immunohorizons; 2019 Mar; 3(3):110-120. PubMed ID: 31240276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
